Because mucosal melanoma ofthe head or neck is uncommon, retrospecti ve data are ofvalue in defin ing its natural history, response to treatment, and patterns of recurrence. We analyze d the medical records of 28 patients who had been treatedf or a mucosa l melanoma ofthe head or neck between 1961 and 1993. We fo und that their cumulative 5-year surviva l rate was 20 %. Patients who had prim ary tumo rs of the nasal cav ity had significa ntly better 5-year survival than other pat ients. Early stage at presentation was another predictor of a more favorable outcome.
Introduction
Althou gh 25% of all mucosal melanomas occur in the head or neck, overall they are uncomm on. Mucosal melanoma represents less than 2% of all malignant melanomas diagnosed in the United States. For exa mple, in a review of 844 U.S. hospitals, an American College of Surgeons study uncovered only 2 1 cases of head or neck mucosal From 
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melan omas durin g the entire year of 1987.' Although the low incidence has lim ited the collection of prospecti ve data, the lethality of these lesions provides encouragement to review retr ospectiv e data to further define the cancer's natural histor y, dissemination, response to treatment, and pattern of recurrence. From 1961 through 1993, 28 patients were treated at the Roswell Park Cancer Institut e in Buffalo, NY , for a diagnosis of primary mucosal melanoma arising in the head or neck. Our review of these patients' record s form s the basis of this report.
Materials and methods
We retrospectively reviewed the record s of 28 patients-15 men and 13 women, aged 23 to 85 (mean: 60)-who had been treated for a diagnosis of mucosal melanoma in the head or neck at our institution between 1961 and 1993. Followup is complete for this entire group .
The most common site of these malign ancies was the nasal cavity (n= 14), followed by the oral cavity (6), the antrum (3), the oroph arynx (2), the hypopharynx (2), and the ethm oid sinus (I ). The mean duration of symptoms was 4.5 months and was longe st for patients who se tumor s were in the nasal cavity and paranasal sinus.
Guided by the presentin g clinical information, we retros pectively staged each patient by primary site using the criteria established by the America n Joint Committee on Cancer (AJCC) (table).' There were 15 early-stage cr,II) patients and 13 patients in advanced stages (III, IV). Only 5 of the 28 patient s presented with a clini cally evident nodal metastasis, but 14 eventually developed a regional metastasis durin g followup. Only 1 patient had a distant metastasis at presentation , but 22 of the 28 (79%) eventually died of a distant metastasis.
Surgical resection was the primary treatment for 17 of the 28 patients; adjuvant radiation therapy was also admini stered to 4 of them and adjuvant chemotherapy to another2. Four patients were treated with radi ation alone, ENT-Ear, Nose & Throat Journal' May 1999 3 patients recei ved only chemothera py, and the remaining 4 recei ved no treatm ent other than supportive care.
Sur vival cur ves were generated by the Kaplan-Meier method, and the log-rank test was used for statistical analysis.
Results
Cumulative survival for the entire gro up at S years was onl y 20% (figure 1). Five-year survival was significantly bette r (p=O.OS ) for pati ent s who presented with stage I or II tumors (32%) than for those with stage III or IV malign ancie s (0%) ( figure 2 ). Unlike what has been rep orted in patients with cutaneous head and neck melanom as, the prognosis for our patients did not differ according to age or gender.' On the other hand , survival did vary according to the site of the primary tumor. The 14 patient s whose primary tumor was in the nasal cav ity had the best S-year surv ival rate (27%; p<O.O I) (fig ure 3 ). Th ere were 3 lon g-term (>S yr) survivors: 2 who had been treated with surg ery alone and I who had been treated with surgery and adjuva nt radiation.
For the 24 treated patients, the mean posttreatment disease-free inte rval was only II mont hs, and the mean time to distant metastasis was only 17 months. Of the 17 patients who had been treated with surgery, 8 deve loped a local recurrence ; 6 of these 8 were aga in rendered disease-free by a repeat resection, but all 6 ultim ately succumbed to a di stant metastasis. Likewise, 6 of the 8 pati ents who had failed regionally were salvage d by neck dissection. Ultimately, local control was achieved in IS of the 17 oper ated patients (88%). Despite this, 13 of the 17 (76%) died of a di stant metastasis. 
Discussion
Head and neck mucosa l melanoma is a rare enti ty with a uniformly poor prognosis for which a lim ited biologic understanding exists. Our series mirrors other reports in demonstrating the differences between this disease and cutaneous head and neck mela nomas. We chose to retrospectively stage these patients acco rding to Al CC criteria for head and neck sites because the tradi tional three-tiered TNM (tumor , nodes, metastases) system places much em phasis on regio nal metastases. The TN M system is of utility in stagi ng cutaneo us melanomas; for example, 40 % of patients in Loree and Spiro' s study of cutaneous head and neck melanoma s presented with node metastases.' However, in mucosal melanoma, the incidence of regional node metastasis at prese ntation has ranged fro m 3 to 23 %,4.11 and in the curre nt series, it was 18% (S/28). There fore , it seems reasonable to use a staging sys tem that emphasizes the extent of local disease. Our surv iva l data showed that patients with T3 and T4 primary tum ors did not fare as well as those with T I and T2 tumors (S-year survival: 0 and 32%, respectively; p=O.OS.)
Our findi ng of amore favorab le outcome for patients whose primary tumor was in the nasal cavi ty was also noted by Stern and Guillamondegui" and by Snow et al." In our series , the generally low stage of the nasal cavi ty tumor likely contributed to the more favorable outcome seen in this group. Local control is an elusive goal in head and neck mucosal melanoma. Even in series where radical surgical resection was used, local recur rence ranged from 3 1 to 8S%.4-6.8.,o.'2The success oflocal salvage followi ng rec urrence has been variable. Conley and Pack repo rted that only 11 % of their patient s who underwent multiple operations for recurr ences achieve d S yea rs of disease co ntrol prior to developin g metastases.' Kingdom and Kaplan recom mend aggress ive resection of local recurrences, as they achieved disease-free intervals of 3 to 40 months in II patie nts with local recurrence.12Lee et al salvaged 24% (5/21) of patients after local relapse." Our local failure rate for resected patients--47% (81 17)-fell within the range of those reported in other publi shed series (31_85%).4.6.8.10.12 However, 6 of the 8 patients who initially failed resection were controlled locally with repeat surgery before they eventually died of a distant metastasis. Despite our high rate of ultimate local control with surgery-88% (l5/17)-distant failure eventually OCCUlTed in 13 of these 17 patients (76%). Our disappointing 5-year survival figure of 20% is within the range of those reported in 10 other published studie s (13-45%) that dealt with primary mucosal melanomas of the head and neck .' :"
Our findings suggest that local control is possible in most patients who undergo a complete surgic al resection of the primary tumor and any subsequent local recurrences that develop. Distant metastasis clearly remains a limiting factor to improving survival. Further improv ements in local and region al treatment, such as with the new high-dose radiation schemes, are unlikel y to improve over all surviv al, even if local control is enhanced."
Effective systemic treatment to control distant metastases, in addition to the best local therapy possible , is the only way real improvement in outcomes will be realized. For example , in a randomized, controlled study of patients with high-risk cutaneous melanomas, 5-year survival was signific antly higher in those who were administered interferon alfa-2b (46%) than in those who were not (37%).1 5It is hoped that interferon alfa-2b will eventually demonstrate similar benefit in patient s with mucosal melanoma. Based on its patterns of relapse and the dissemination, all patients with mucosal melanoma are at high risk for local recurrence, distant metastasis, and death from disease .
